# mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer

> **NCT03043729** · PHASE2 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 119 (actual)

## Conditions studied

- Rectal Cancer
- Rectosigmoid Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** 5-FU
- **DRUG:** Leucovorin
- **BIOLOGICAL:** Aflibercept

## Key facts

- **NCT ID:** NCT03043729
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-06
- **Primary completion:** 2021-01-11
- **Final completion:** 2022-06-01
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2023-02-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03043729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03043729, "mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03043729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*